Hospital Infection Therapeutics Market Status and Trend Analysis 2017-2026 (COVID-19 Version)
- 99S4163331
- 90 Pages
- January 2020
- Medical Devices
Further key aspects of the report indicate that:
Chapter 1: Research Scope: Product Definition, Type, End-Use & Methodology
Chapter 2: Global Industry Summary
Chapter 3: Market Dynamics
Chapter 4: Global Market Segmentation by region, type and End-Use
Chapter 5: North America Market Segmentation by region, type and End-Use
Chapter 6: Europe Market Segmentation by region, type and End-Use
Chapter 7: Asia-Pacific Market Segmentation by region, type and End-Use
Chapter 8: South America Market Segmentation by region, type and End-Use
Chapter 9: Middle East and Africa Market Segmentation by region, type and End-Use.
Chapter 10: Market Competition by Companies
Chapter 11: Market forecast and environment forecast.
Chapter 12: Industry Summary.
The global Hospital Infection Therapeutics market has the potential to grow with xx million USD with growing CAGR in the forecast period from 2021f to 2026f. Factors driving the market for @@@@@ are the significant development of demand and improvement of COVID-19 and geo-economics.
Based on the type of product, the global Hospital Infection Therapeutics market segmented into
Antibacterial Drugs
Antiviral Drugs
Antifungal Drugs
Based on the end-use, the global Hospital Infection Therapeutics market classified into
Hospital-Acquired Pneumonia
Urinary Tract Infections
Gastrointestinal Disorders
Bloodstream Infections
Surgical Site Infections
Other Hospital Infections
Based on geography, the global Hospital Infection Therapeutics market segmented into
North America [U.S., Canada, Mexico]
Europe [Germany, UK, France, Italy, Rest of Europe]
Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]
South America [Brazil, Argentina, Rest of Latin America]
Middle East & Africa [GCC, North Africa, South Africa, Rest of Middle East and Africa]
And the major players included in the report are
Sanofi
Pfizer
Merck
Bayer
Johnson & Johnson
AstraZeneca
Actavis
Bristol-Myers Squibb Company
Cubist Pharmaceuticals
GlaxoSmithKline
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL HOSPITAL INFECTION THERAPEUTICS INDUSTRY
2.1 Summary about Hospital Infection Therapeutics Industry
2.2 Hospital Infection Therapeutics Market Trends
2.2.1 Hospital Infection Therapeutics Production & Consumption Trends
2.2.2 Hospital Infection Therapeutics Demand Structure Trends
2.3 Hospital Infection Therapeutics Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 Antibacterial Drugs
4.2.2 Antiviral Drugs
4.2.3 Antifungal Drugs
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Hospital-Acquired Pneumonia
4.3.2 Urinary Tract Infections
4.3.3 Gastrointestinal Disorders
4.3.4 Bloodstream Infections
4.3.5 Surgical Site Infections
4.3.6 Other Hospital Infections
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 Antibacterial Drugs
5.2.2 Antiviral Drugs
5.2.3 Antifungal Drugs
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Hospital-Acquired Pneumonia
5.3.2 Urinary Tract Infections
5.3.3 Gastrointestinal Disorders
5.3.4 Bloodstream Infections
5.3.5 Surgical Site Infections
5.3.6 Other Hospital Infections
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 Antibacterial Drugs
6.2.2 Antiviral Drugs
6.2.3 Antifungal Drugs
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Hospital-Acquired Pneumonia
6.3.2 Urinary Tract Infections
6.3.3 Gastrointestinal Disorders
6.3.4 Bloodstream Infections
6.3.5 Surgical Site Infections
6.3.6 Other Hospital Infections
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 Antibacterial Drugs
7.2.2 Antiviral Drugs
7.2.3 Antifungal Drugs
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Hospital-Acquired Pneumonia
7.3.2 Urinary Tract Infections
7.3.3 Gastrointestinal Disorders
7.3.4 Bloodstream Infections
7.3.5 Surgical Site Infections
7.3.6 Other Hospital Infections
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 Antibacterial Drugs
8.2.2 Antiviral Drugs
8.2.3 Antifungal Drugs
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Hospital-Acquired Pneumonia
8.3.2 Urinary Tract Infections
8.3.3 Gastrointestinal Disorders
8.3.4 Bloodstream Infections
8.3.5 Surgical Site Infections
8.3.6 Other Hospital Infections
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 Antibacterial Drugs
9.2.2 Antiviral Drugs
9.2.3 Antifungal Drugs
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Hospital-Acquired Pneumonia
9.3.2 Urinary Tract Infections
9.3.3 Gastrointestinal Disorders
9.3.4 Bloodstream Infections
9.3.5 Surgical Site Infections
9.3.6 Other Hospital Infections
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Sanofi
10.1.2 Pfizer
10.1.3 Merck
10.1.4 Bayer
10.1.5 Johnson & Johnson
10.1.6 AstraZeneca
10.1.7 Actavis
10.1.8 Bristol-Myers Squibb Company
10.1.9 Cubist Pharmaceuticals
10.1.10 GlaxoSmithKline
10.2 Hospital Infection Therapeutics Sales Date of Major Players (2017-2020e)
10.2.1 Sanofi
10.2.2 Pfizer
10.2.3 Merck
10.2.4 Bayer
10.2.5 Johnson & Johnson
10.2.6 AstraZeneca
10.2.7 Actavis
10.2.8 Bristol-Myers Squibb Company
10.2.9 Cubist Pharmaceuticals
10.2.10 GlaxoSmithKline
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT
1.Table Hospital Infection Therapeutics Product Type Overview
2.Table Hospital Infection Therapeutics Product Type Market Share List
3.Table Hospital Infection Therapeutics Product Type of Major Players
4.Table Brief Introduction of Sanofi
5.Table Brief Introduction of Pfizer
6.Table Brief Introduction of Merck
7.Table Brief Introduction of Bayer
8.Table Brief Introduction of Johnson & Johnson
9.Table Brief Introduction of AstraZeneca
10.Table Brief Introduction of Actavis
11.Table Brief Introduction of Bristol-Myers Squibb Company
12.Table Brief Introduction of Cubist Pharmaceuticals
13.Table Brief Introduction of GlaxoSmithKline
14.Table Products & Services of Sanofi
15.Table Products & Services of Pfizer
16.Table Products & Services of Merck
17.Table Products & Services of Bayer
18.Table Products & Services of Johnson & Johnson
19.Table Products & Services of AstraZeneca
20.Table Products & Services of Actavis
21.Table Products & Services of Bristol-Myers Squibb Company
22.Table Products & Services of Cubist Pharmaceuticals
23.Table Products & Services of GlaxoSmithKline
24.Table Market Distribution of Major Players
25.Table Global Major Players Sales Revenue (Million USD) 2017-2020e
26.Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e
27.Table Global Hospital Infection Therapeutics Market Forecast (Million USD) by Region 2021f-2026f
28.Table Global Hospital Infection Therapeutics Market Forecast (Million USD) Share by Region 2021f-2026f
29.Table Global Hospital Infection Therapeutics Market Forecast (Million USD) by Demand 2021f-2026f
30.Table Global Hospital Infection Therapeutics Market Forecast (Million USD) Share by Demand 2021f-2026f
Similar Reports
This report provides an overview of the French molecular diagnostic testing market, including test volume, and sales forecasts by Application, 2019-2023, and supplier shares by test.
Table of Contents
Business Environment
Market Structure
Market Size, Growth, and Major Suppliers' Market Shares
This report provides an overview of the German molecular diagnostic testing market, including test volume, and sales forecasts by application, and supplier shares by test.
Table of Contents
Business Environment
Market Structure
Market Size, Growth, and Major Suppliers' Market Shares
&nb...
- Publish Date: April 1, 2019
- $450
This report provides an overview of the Italian molecular diagnostic testing market, including test volume, and sales forecasts by application, and supplier shares by test.
Table of Contents
Business Environment
Market Structure
Market Size, Growth, and Major Suppliers' Market Shares
&nb...
- Publish Date: April 1, 2019
- $450
